Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Pheochromocytoma 1Paraganglioma 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Oxyphilic 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 10Paclitaxel 7Iodine-131 6Fluorodeoxyglucose F18 6Sorafenib 5vandetanib 4trametinib 4selpercatinib 4dabrafenib 4pembrolizumab 3fosbretabulin 3cabozantinib 3Vemurafenib 3Sunitinib 3Specimen Handling 3Nivolumab 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2romidepsin 2pazopanib 2lenvatinib 2combretastatin 2Trastuzumab 2Thyrotropin Alfa 2Ipilimumab 2Gefitinib 2FAPI-46 2Everolimus 2Doxorubicin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × spartalizumab × Endocrine × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡